. 2021 May 5;9(3):635–648. doi: 10.1002/iid3.439

Table 1.

Patient and study characteristics

Study, year	Location	Patients, total	AR status	Ages	Gender, n male (%)	Asthma (%)	Medication
Henriksen (1999) ¹¹	Norway	AR 46 (Seasonal19, Seasonal + perennial27), HC 12	Symptomatic	AR: 16.4 (13–20); HC: 17.8 (16–19)	29/58 (50.0%)	0	Antihistamines
Palm (2003) ¹⁸	Sweden	AR 18, HC 18	Symptomatic	AR: 32 (21–50); HC: 30 (20–46)	18/36 (50%)	0	No steroid, no antihistamines
Makris (2011) ¹⁹	Greece	SAR 26, HC 15	Symptomatic	AR 28.4 (16–47); HC 37.1 (27–56);	22/41 (53.7%)	0	No corticosteroids, no antihistamines
Lee (2012) ⁷	Korea	AR 35, patients with deviated nasal septa as HC 34	Not mentioned	AR: 22.7 ± 8.7; HC: 26.9 ± 11.0	42/69 (60.9%)	0	No nasal medication
Suojalehto (2014) ²⁰	Finland	AR 89, NAR 44, HC 42	Not mentioned	AR: 32.9 ± 1.3; NAR: 33.2 ± 1.5; HC: 33.5 ± 1.8	62/175 (35.4%)	42.7	No nasal steroids
Nesic (2016) ⁸	Serbia	AR 23, HC 10	Not mentioned	AR: 33.4 ± 11.1; HC: 33.3 ± 8.4	18/33 (55%)	0	No steroids
Hou (2018) ²¹	China	AR 75, HC 31	Symptomatic	AR: 36.24 ± 10.96; HC: 35.32 ± 12.11	65/106 (61.3%)	0	No nasal steroids, no antihistamine
Mu (2019) ²²	China	AR concomitant with asthma 65, HC 40	Not mentioned	AR 7.2 ± 1.9; HC7.2 ± 0.7	68/105 (64.8%)	100	Not mentioned
Wen (2019) ²³	China	PAR 90, HC 79	Not mentioned	AR: 9.7 ± 2.4; HC: 10.1 ± 1.9	116/169 (68.6%)	0	No corticosteroids, no leukotriene receptor antagonist
Liu (2020) ²⁴	China	AR 94, NAR 79, patients diagnosed with pituitary tumor or lateral skull base mass as HC 46	Symptomatic	AR: 30.5 ± 8.9; NAR: 37.7 ± 14.1; HC: 30.7 ± 5.5	160/219 (73.1%)	0	No corticosteroids

Note: Data is expressed in mean ± SD or mean (range).

Abbreviations: AR, allergic rhinitis; HC, healthy controls; n, number; NAR, nonallergic rhinitis; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis.